Market does not believe the myths - from the GM bankruptcy look at the adjustment of facing the pharmaceutical industry.doc

 PAGE \* MERGEFORMAT 7 Market does not believe the myths - from the GM bankruptcy look at the adjustment of facing the pharmaceutical industry Eliminated not do: adapt to changes in consumer demand General phenomenon: in the United States an adequate energy supply situation, there is no oil crisis, the common sense of the major developments are the traditional gas-guzzling SUV and other models, and energy-saving emission reduction trend of the world contrary to the Galaxy, in energy prices the general trend, the U.S. auto industry will naturally be in trouble. At the same time, General Motors R amp;amp; D for new products are too far ahead of 10 years, its development of new energy vehicles poured into the full, but the common soldier’s onrush, complete failure to consider the global energy structure. Thinking: the neglect of the traditional mainstream product market demand, new product markets ignore the reality of the situation and eventually lead to universal defeat. A similar situation has occurred in the Chinese pharmaceutical companies who. National Development and Reform Commission from the beginning of the century since the first large-scale price cuts, and numerous pharmaceutical drug prices suffered a crisis. Company main product had 80% lower prices, but the development of the first imitation of another drug was put on the market soon is not yet mature, the need to cultivate, enterprise lean, narrowly escaped elimination. Of course, after more than 20 times to force price cuts, despite the Chinese pharmaceutical companies complain incessantly, it seems to have adapted. However, when an even greater crisis strikes, companies will have to make a reborn consideration. In fact, the survival of China’s pharmaceutical companies have been relatively favorable environment for many years, attracted numerous pharmaceutical companies coveting the world and actively advance. Industry experts had in the ‘United Kingdom: brand-name drugs struggling’ a text tha